{
    "id": "4e331c09-8557-4851-9d1b-884eafe08c8f",
    "indications": "milrinone indicated short-term intravenous treatment patients acute decompensated heart failure . patients receiving milrinone observed closely appropriate electrocardiographic equipment . facility immediate treatment potential cardiac events , may include life-threatening ventricular arrythmias , must available . majority experience intravenous milrinone patients receiving digoxin diuretics . experience controlled trials infusions milrinone periods exceeding 48 hours .",
    "contraindications": "milrinone administered loading dose followed continuous infusion ( maintenance dose ) according following guidelines :",
    "warningsAndPrecautions": "baxter ’ milrinone lactate 5 % dextrose injection supplied intravia plastic container follows : 2j0900 ndc 0338-6010-48 100 ml ( 200 mcg/ml ) 2j0901 ndc 0338-6011-37 200 ml ( 200 mcg/ml ) exposure pharmaceutical products heat minimized . avoid excessive heat . protect freezing . recommended product stored room temperature , 25° c ( 77° f ) ; however , brief exposure 40° c ( 104° f ) adversely affect product .",
    "adverseReactions": "milrinone contraindicated patients hypersensitive . solutions containing dextrose may contraindicated patients known allergy corn corn products .",
    "ingredients": [
        {
            "name": "MILRINONE LACTATE",
            "code": "9K8XR81MO8"
        },
        {
            "name": "LACTIC ACID",
            "code": "33X04XA5AT"
        },
        {
            "name": "DEXTROSE MONOHYDRATE",
            "code": "LX22YL083G"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "organization": "Baxter Healthcare Corporation",
    "name": "Milrinone Lactate in Dextrose",
    "effectiveTime": "20180530",
    "indications_original": "Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours.",
    "contraindications_original": "Milrinone should be administered with a loading dose followed by a continuous infusion (maintenance dose) according to the following guidelines:",
    "warningsAndPrecautions_original": "Baxter’s Milrinone Lactate in 5% Dextrose Injection is supplied in INTRAVIA Plastic Container as follows:\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                               2J0900 \n                           \n                           \n                               NDC 0338-6010-48 \n                           \n                           \n                               100 mL (200 mcg/mL) \n                           \n                        \n                        \n                           \n                               2J0901 \n                           \n                           \n                               NDC 0338-6011-37 \n                           \n                           \n                               200 mL (200 mcg/mL) \n                           \n                        \n                     \n                  \n                  Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at room temperature, 25° C (77° F); however, brief exposure up to 40° C (104° F) does not adversely affect the product.",
    "adverseReactions_original": "Milrinone is contraindicated in patients who are hypersensitive to it.\n                  Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products."
}